ZVRA

Zevra Therapeutics Announces Positive Phase 2 Trial Of KP1077 For Idiopathic Hypersomnia

(RTTNews) - Zevra Therapeutics, Inc. (ZVRA) Monday announced a positive outcome in its placebo-controlled, double-blind Phase 2 clinical trial of KP1077 or serdexmethylphenidate or SDX in patients with idiopathic hypersomnia.

The proof-of-concept study was designed to demonstrate safety and tolerability and was well tolerated at all dose levels evaluated in the trial. The company presented the data in a poster at SLEEP 2024 in Houston, TX.

Adrian Quartel, chief medical officer of Zevra said, "We believe that KP1077 has great potential to provide a differentiated treatment option for patients underserved by currently available therapies."

Idiopathic hypersomnia is a rare sleep disorder characterized by excessive daytime sleepiness.

ZVRA is currently at $4.83, up 3.98 percent from the previous close of $4.65 on a volume of 108,488.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Tags

More Related Articles

Info icon

This data feed is not available at this time.

Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education. Delivered Wednesdays.